LPCN (Lipocine Inc) רווח למניה בארבעת הרבעונים האחרונים

Lipocine Inc. effectively delegates mass drug production to global CMO networks while maintaining strict oversight of contracts. Innovations in oral hormone delivery allow the company to command premium pricing during licensing. The business model relies on third-party molecule synthesis without owning its own plants. In the EPS YoY TTM shift metric, the value -33.50 serves as the current indicator capturing the market consensus on the annual profit growth rate.
LPCN (Lipocine Inc.): פילוחים אנליטיים ודוחות לפי אינדיקטורים

This indicator measures the annual rate of change in net income per share over the last twelve months, allowing for a real-time assessment of capital generation efficiency. By analyzing the EPS YoY TTM percentage trend, an investor can identify the critical dependence of Lipocine Inc. (LPCN) on FDA approvals and the risks of shareholder dilution resulting from regular secondary offerings.